Simulations Plus Releases New Simulation Software

Simulations Plus Inc., a Lancaster-based developer of drug development simulation software for the pharmaceutical industry, has released Version 1.1.1 of its GastroPlus simulation software, used to predict the absorption of drugs by the human digestive system.

GastroPlus is currently licensed to eight pharmaceutical companies. The company has two other businesses, Words+ and FutureLab, which are based on its software technologies. The company trades on the NASDAQ under the symbol SIMU.